Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,440 stopped studies mapped to Adenocarcinoma and descendants · 92% state a reason
Over the 1,440 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of… | Phase 1 / Phase 2 | withdrawn | Aug 6, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01918306 | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple… | Phase 1 / Phase 2 | terminated | Aug 7, 2013 | Vanderbilt-Ingram Cancer Center | company stopped production of study drug due to excessive toxicities, lack of efficacy | Safety / toxicity |
| NCT01936961 | Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid…(I-CREST) | N/A | withdrawn | Sep 6, 2013 | Western Regional Medical Center | No patients enrolled | Enrollment / accrual |
| NCT01148082 | School Response to Families Who Have Children With Cancer | — | withdrawn | Jun 22, 2010 | Stanford University | Business decision | Sponsor / business decision |
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating… | Phase 1 / Phase 2 | terminated | Sep 28, 2007 | Roswell Park Cancer Institute | difficult to recruit | Enrollment / accrual |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal…(5-AZ) | Phase 1 / Phase 2 | terminated | Jul 8, 2009 | University of Kansas Medical Center | not stated | Not stated |
| NCT01599832 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib… | N/A | terminated | May 16, 2012 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT00632203 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV… | Phase 2 | terminated | Mar 10, 2008 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic… | Phase 2 | terminated | Nov 10, 2008 | University of Washington | not stated | Not stated |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | Phase 2 | terminated | Jul 29, 2014 | Millennium Pharmaceuticals, Inc. | Business Decision, No Safety or Efficacy Concerns | Safety / toxicity |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | terminated | Jul 29, 2009 | Massachusetts General Hospital | Funding was withdrawn after only 10 participants were enrolled | Enrollment / accrual |
| NCT01005875 | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma(RAD 0901) | N/A | terminated | Nov 2, 2009 | University of Alabama at Birmingham | Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is… | Enrollment / accrual |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to… | Phase 1 | terminated | Sep 13, 2013 | Korea Otsuka Pharmaceutical Co., Ltd. | Company decision | Sponsor / business decision |
| NCT02856867 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric…(MEGAN) | Phase 2 | withdrawn | Aug 5, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | not stated | Not stated |
| NCT01882231 | Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma | N/A | terminated | Jun 20, 2013 | Vanderbilt-Ingram Cancer Center | Slow accrual and lack of funding | Enrollment / accrual |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | Phase 2 | terminated | Jun 23, 2011 | Novartis Pharmaceuticals | The study was terminated due to low enrollment. This resulted in the study being underpowered and… | Enrollment / accrual |
| NCT01476553 | Elimination of Peritoneal Tumor Cells With Extensive Peritoneal Lavage During Surgery in…(EIPL) | N/A | terminated | Nov 22, 2011 | Universitätsmedizin Mannheim | Prematurely halted after interim data analysis | Other (stated, no rule matched) |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced… | Phase 1 / Phase 2 | withdrawn | Aug 28, 2014 | Amgen | Study stopped due to administrative reasons | Other (stated, no rule matched) |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | — | terminated | Apr 3, 2007 | National Health Research Institutes, Taiwan | No cases enrollment | Enrollment / accrual |
| NCT01913015 | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic… | Phase 1 | terminated | Jul 31, 2013 | OHSU Knight Cancer Institute | After enrollment of the first 3 subjects, an interim assessment was conducted. Comparing DBS… | Enrollment / accrual |
| NCT02840162 | Pre-Prostatectomy Celecoxib or Placebo | Phase 2 | terminated | Jul 21, 2016 | OHSU Knight Cancer Institute | Drug safety concerns | Safety / toxicity |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular… | Phase 2 | terminated | Jul 28, 2010 | Seoul National University Hospital | There were problems with national reimbursement policies. | Other (stated, no rule matched) |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing… | Phase 1 / Phase 2 | withdrawn | Dec 20, 2016 | University of Michigan Rogel Cancer Center | funding issues | Funding |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | Phase 4 | terminated | May 8, 2013 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | Phase 2 | terminated | Jun 30, 2016 | Taipei Medical University WanFang Hospital | insufficient for the fund | Funding |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct… | Phase 1 | withdrawn | Apr 18, 2017 | City of Hope Medical Center | Company no longer interested in supporting this trial | Sponsor / business decision |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients…(PRIMIER) | Phase 2 | withdrawn | Apr 10, 2015 | University of Southern California | Study drug supply issues | Drug supply |
| NCT01729832 | Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast… | N/A | withdrawn | Nov 20, 2012 | Ohio State University Comprehensive Cancer Center | not stated | Not stated |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | Phase 2 | terminated | Jan 20, 2017 | City of Hope Medical Center | Due to Sorafenib became first line treatment for HCC, the designed treatment became less… | Sponsor / business decision |
| NCT03113604 | Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in…(SLAMF3) | — | withdrawn | Apr 13, 2017 | Centre Hospitalier Universitaire, Amiens | The study has been stopped because no one is | Other (stated, no rule matched) |
| NCT00651482 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001… | Phase 2 | terminated | Apr 2, 2008 | Sandy Srinivas | slow accrual | Enrollment / accrual |
| NCT01151449 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With… | Phase 2 | terminated | Jun 28, 2010 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
| NCT01729884 | Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer | Phase 2 | terminated | Nov 20, 2012 | University of Washington | Study ended early due to slow enrollment | Enrollment / accrual |
| NCT02071641 | Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Feb 26, 2014 | Amsterdam UMC, location VUmc | not stated | Not stated |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients… | Phase 2 | withdrawn | Jan 5, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem… | Phase 2 | terminated | Jun 17, 2008 | University of Arizona | Pentostatin/alemtuzumab regimen had greater risk of graft failure. | Other (stated, no rule matched) |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary… | Phase 2 | terminated | Oct 27, 2010 | National Cancer Institute (NCI) | Lack of Drug Supply | Drug supply |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma… | Phase 1 | terminated | Mar 18, 2015 | Millennium Pharmaceuticals, Inc. | The study was terminated because preliminary PK and overall clinical data demonstrated compelling… | Other (stated, no rule matched) |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | Phase 3 | terminated | Jul 29, 2011 | National Cancer Institute, Naples | lack of enrolment | Enrollment / accrual |
| NCT00127036 | Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) | Phase 2 | terminated | Aug 5, 2005 | H. Lee Moffitt Cancer Center and Research Institute | drug now on market | Other (stated, no rule matched) |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | Phase 1 | terminated | Dec 24, 2014 | Celgene | Slow enrollment and business decision. No safety concerns were identified for the study drugs. | Safety / toxicity |
| NCT01943188 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With… | Phase 1 | terminated | Sep 16, 2013 | Stanford University | not stated | Not stated |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple-… | Phase 2 | withdrawn | Feb 18, 2016 | Peregrine Pharmaceuticals | not stated | Not stated |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | Phase 2 | terminated | Dec 18, 2007 | University of Pittsburgh | Bayer Healthcare is no supplying the study drug | Other (stated, no rule matched) |
| NCT01441765 | PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | Phase 2 | terminated | Sep 28, 2011 | Beth Israel Deaconess Medical Center | Funding | Funding |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of… | Phase 2 | withdrawn | Jul 16, 2012 | Imunon | not stated | Not stated |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate… | Phase 1 / Phase 2 | terminated | Apr 10, 2009 | John P. Fruehauf | Terminated due to slow accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 2, 2017source: clinicaltrials